The effect of weight loss medication, conjugated linoleic acid on body fat in obese individuals.

Randomised Double Blind Prospective Controlled Study Of The Effect Of 12 Weeks Treatment With Conjugated Linoleic Acid Supplementation On Body Fat Mass And Lipid Metabolism In Healthy Obese Individuals

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

CTRI

Registry ID

CTRI/2018/04/013289

Enrollment

220

Registered

2018-04-16

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Intervention1: Conjugated linoleic acid 500 mg, an anti obesity medication: It is a neutraceutical, contains omega-6 fatty acid, green tea extract and chromium picolinate. 500 mg capsule 1 b.d. for 3

Eligibility

Inclusion criteria

Inclusion criteria: Body mass index 30 Kg/Square meter ormoe Waist circumference >104 cm or more in men and 88 cm or moe in woment

Exclusion criteria

Exclusion criteria: Endocrine disorders Allergic disorders Pregnancy and lactation Management for weight control within previous 3 months Any other condition deemed unsuitable for the trial

Design outcomes

Primary

Measure	Time frame
A reduction in the body fat mass as measured by Karada scan after treatment with Conjugated Linoleic acidTimepoint: A reduction in the body fat mass as measured by Karada scan after treatment with Conjugated Linoleic acid after 12 weeks treatment	—

Secondary

Measure	Time frame
A reduction in the lipid profile and HS- CRP valuesTimepoint: A reduction in the lipid profile and HS-CRP after 12 weeks treatment with conjugated linoleic acid	—

Countries

India

Contacts

Public ContactLalitha Devi Bhyravavajhula

GSL Medical college

lalithadevi@gslmc.com

Outcome results